Biosyent Inc. (BIOYF)
BioSyent Inc. is a Canada-based healthcare company focused on acquiring, licensing, developing, and marketing pharmaceutical and other healthcare products in Canada and international markets. The company’s portfolio includes products used in areas such as iron deficiency anemia, hormone replacement therapy, polycystic ovarian syndrome symptoms, vaginal dryness and mucosal healing, oral mucositis pain relief, catheterization support, and rectal healing. Key products cited include FeraMAX Pd Therapeutic 150, FeraMAX Pd Maintenance 45, FeraMAX Pd Powder 15, Tibella, Inofolic, RepaGyn, Gelclair, Cathejell, and Proktis-M. BioSyent distributes its products through wholesalers and retail pharmacy chains. Incorporated in 2006 and formerly known as Hedley Technologies Inc., the company is headquartered in Mississauga, Canada. The listed security is common stock on OTC Markets.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
OTC-BIOY.F
|
$10.66
|
3.2% Upside
|
Fair
|
—
|
—
|
—
|
Great
|
—
|
—
|
0.16
|
1.5%
|
August 25, 2026
|
18.5x
|
3.7x
|
3.6x
|
118 M
|
114 M
|
3.1%
|
80.9%
|
13.7
|
25.5%
|
137.2%
|
